Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT06693674

Effect of Sacubitril-Valsartan on Cardiac Structure and Function

Conditions: Congenital Heart Disease

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 45

Sponsor: Mayo Clinic

Location: Mayo Clinic in Rochester Rochester Minnesota

Summary

The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.

Eligibility Criteria

Inclusion Criteria: * Congenital Heart Disease Diagnosis * Age 18 or Older Exclusion Criteria: * Stage IV chronic kidney disease defined as creatinine clearance \5.2 mmol/l, * Hypotension defined as systolic blood pressure \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06693674). StuddyBuddy aggregates publicly available trial information.